Caris Life Sciences published a study identifying 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types.
The study analyzed 87 biomarker-directed FDA approvals from 2018 to 2025, with about one-third meeting Lookback Program criteria.
Since 2014, the program monitors FDA approvals and identifies patients whose molecular profiles match new recommendations without additional testing.
